Navigation Links
Ex-IITian-designed Alzheimer's Drug's Human Clinical Trials Begin

Purdue University researchers have begun the first phase of human clinical trials to test the efficacy of an Alzheimer's drug designed in-house.

The drug is based on an inhibitor developed by a team of researchers at the university. The researchers say that it may help intercept and disable the disease at an early stage.

"Millions of people suffer from this devastating disease and treatment options are very limited," said Professor Arun Ghosh, who led the creation of the treatment molecule.

"Current drugs manage the symptoms, but this could be the first disease-modifying therapy. It may be able to prevent and reverse the disease," Ghosh, who did his MSc from MSc, Indian Institute of Technology, Kanpur in 1981.

CoMentis Inc., a San Francisco-based biopharmaceutical firm co-founded by Professor Ghosh and Oklahoma Medical Research Foundation (OMRF) scientist Jordan Tang, is initiating the clinical trials of the experimental drug CTS-21166.

The trial, which comprises of 48 healthy volunteers, will measure safety, tolerability, and pharmacokinetics of CTS-21166 at various doses.

Its results are expected to be out by the end of 2007, and the researchers expect to begin phase II studies in Alzheimer's patients in 2008.

In 2000, Professor Ghosh had built an inhibitor that had the ability to bind to and inactivate the beta-secretase enzyme, which is significant to the progression of Alzheimer's. Since then he has been leading the structure-based design of these inhibitors for therapeutic intervention of the disease.

His most recent work, which led to the creation of beta-secretase inhibitor CTS-21166, was published in the Journal of Medicinal Chemistry.

"The molecule is both highly potent and highly selective, meaning it does not appear to affect other enzymes important to brain function or cause harmful side effects," Professor Ghosh said.

"It took years of work and evaluation of hundreds of molecules to achieve one with the strength and safety necessary for clinical potential," he added.


'"/>




Related medicine news :

1. Evidence Links Protein Damage to Neurodegenerative diseases like Parkinsons and Alzheimers
2. Decrease in testosterone levels lead to Alzheimers
3. Smokers are prone to Alzheimers
4. Over-The-Counter Drugs May Prevent Alzheimers
5. Alzheimers followed by head injury
6. Vitamin E useful for Alzheimers
7. Staying mentally energitic prevents Alzheimers
8. Researchers trick Alzheimers Enzyme
9. Drug Offers Hope for Alzheimers disease
10. Alzheimers with psychosis runs in families
11. Blood test may aid foretell Alzheimers
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... "FCPX editors ... customizable inside of Final Cut Pro X," said Christina Austin - CEO of Pixel ... style. Final Cut Pro X users can now reveal the media of ...
(Date:6/26/2016)... (PRWEB) , ... June 27, 2016 , ... Quality metrics ... yet in many ways they remain in the eye of the beholder, according to ... a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... Birmingham, Lake Orion, Clarkston, Michigan (PRWEB) , ... ... ... their direction with respect to fertility once they have been diagnosed with endometriosis. ... for tolerable intercourse but they also require a comprehensive approach that can help ...
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, ... Board will take whatever measures required to build a ... stock which is currently listed on the OTC Markets-pink ... Company Chairman and CEO, "We are seeing an anomaly ... to understand, not only by the Company, but shareholders ...
(Date:6/24/2016)... N.J. , June 24, 2016  Collagen ... the design, development and manufacturing of collagen and ... regeneration announced today that Bill Messer ... and Marketing to further leverage the growing portfolio ... medical devices. Bill joins the Collagen ...
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... and Markets has announced the addition of the ... their offering. ... products and provides an updated review, including its applications ... covering the total market, which includes three main industries: ...
Breaking Medicine Technology: